The arrival of a great number of new antineoplastic agents has made it necessary to reclassify all of them. Anticancer drugs may act at different levels: cancer cells, endothelium, extracellular matrix, the immune system or host cells. The tumour cell can be targeted at the DNA, RNA or prote...
The arrival of a great number of new antineoplastic agents has made it necessary to reclassify all of them. Anticancer drugs may act at different levels: cancer cells, endothelium, extracellular matrix, the immune system or host cells. The tumour cell can be targeted at the DNA, RNA or prote...
Classification of anticancer drugs--a new system based on therapeutic targets. Cancer Treat. Rev. 29, 515-523 (2003). 58Espinosa E, Zamora P, Feliu J, et al. Classification of anticancer drugs-a new system based on thera- peutic targets. Cancer Treat Rev 2003;29(6):515-23....
Relation analysis performed by partial least squares-discriminant analysis (PLS-DA) indicated that in comparison with the control group, the media amino-acid consumption profiling can distinguish the two anticancer drugs with different mechanisms, which provides a new perspective for the pre-...
Antimetabolites are a class of anticancer drugs that work by interfering with DNA synthesis to kill cancer cells. 5-fluorouracil (5-FU), capecitabine, floxuridine, cytarabine, gemcitabine, decitabine, and vidaza are some of the most important medications in this class. These compounds are pyrimidine...
These natural compounds have been documented as exerting several chemopreventive and anticancer effects27,28. However, the selective mechanisms of these three natural compounds on protein kinases remain unclear, particularly for rosmarinic acid. Kinase profiling for type-C inhibitors. Here, we used ...
Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs Pharm. Res., 13 (1996), pp. 272-278 View in ScopusGoogle Scholar Merisko-Liversidge et al., 2003 E. Merisko-Liversidge, G.G. Liversidge, E.R. Cooper Nanosizing: a formulation approac...
Anticancer Drugs, 32 (3) (2021), pp. 314-322 CrossrefView in ScopusGoogle Scholar [69] M. Wu, et al. TRPS1 knockdown inhibits angiogenic vascular mimicry in human triple negative breast cancer cells Clin. Transl. Oncol., 24 (1) (2022), pp. 145-153 CrossrefView in ScopusGoogle Schol...
H. The NCI60 human tumour cell line anticancer drug screen. Nature reviews. Cancer 6, 813–823, doi: 10.1038/nrc1951 (2006). Article PubMed CAS Google Scholar Petit, T. et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as ...
Anticancer Drugs. 25:512–521. 2014. View Article : Google Scholar : PubMed/NCBI 72 Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al: Pathological complete response and long-term clinical benefit in breast cancer...